The White House appointed former Glaxosmithkline plc vaccines chief Moncef Slaoui as chief advisor of Operation Warp Speed, the Trump administration's new national program to accelerate the development, manufacturing and distribution of COVID-19 vaccines, therapeutics and diagnostics. One of the efforts is "to have substantial quantities of a safe and effective vaccine available for Americans by January 2021." In addition to Slaoui, and General Gustave Perna, who will act as chief operating officer for the effort, FDA leaders Peter Marks and Janet Woodcock along with Bruce Tromberg, director of the NIH's National Institute of Biomedical Imaging and Bioengineering, will work on the project. As a condition of receiving support from Operation Warp Speed, companies will provide a donated allocation of countermeasures developed, including an eventual vaccine, the administration said. "The federal government is making investments in manufacturing and distribution at its own risk much earlier than usual, giving firms confidence that they can invest aggressively in development of countermeasures," the government said in a statement about the effort.